López-Guillermo A, García-Conde J, Alvarez-Carmona A M, León P, Maldonado J, Alcalá A, Zubizarreta A, Sancho-Tello R, Carbonell F, Contreras E, Besses C, Hernando A, Fontanillas M, Montserrat E
Servicio de Hematología, Hospital Clínic i Provincial, Villarroel, Barcelona.
Med Clin (Barc). 1998 May 9;110(16):601-4.
To compare standard chemotherapy CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) with the regimen CHOP/VIA (VP-16, iphosphamide and cytarabine) in terms of response to therapy, response duration, survival and toxicity in patients with aggressive lymphoma.
132 patients (84 males and 48 females; median age, 55 years) were included from 12 Spanish Institutions, diagnosed of non-Hodgkin's lymphoma of intermediate or high grade, in stages II-IV and previously untreated. Patients were randomized to receive CHOP or CHOP/VIA.
After excluding 14 not assessable cases, 62 patients (52.5%) received CHOP, and 56 (47.5%) CHOP/VIA. No significant differences were found on main prognostic factors between such groups. Response was assessable in 114 cases (CHOP: 61; CHOP/VIA: 53) 39 patients (64%) receiving CHOP achieved complete response (CR), and 2 (3%) partial response (PR), whereas in the CHOP/VIA group CR and PR rates were 63% (34/53), and 7% (4/53), respectively. 14 patients (36%) treated with CHOP and 12 (35%) treated with CHOP/VIA eventually relapsed, with an actuarial risk of relapse at 36 months of 43% and 40%, respectively. Median survival was 37 months. No differences were found between both therapeutic groups, with an overall survival at 36 months from diagnosis of 53.5% (CI 95%: 40-67) for CHOP and 48% (CI 95%: 34-62) for CHOP/VIA. Finally, toxicity was not different for both arms.
In the present study in patients with aggressive NHL chemotherapy regimens CHOP and CHOP/VIA showed similar results in terms of response, response duration, survival and toxicity.
比较标准化疗方案CHOP（环磷酰胺、阿霉素、长春新碱和泼尼松）与CHOP/VIA方案（依托泊苷、异环磷酰胺和阿糖胞苷）在侵袭性淋巴瘤患者中的治疗反应、反应持续时间、生存率和毒性。
来自12家西班牙机构的132例患者（84例男性，48例女性；中位年龄55岁）被纳入研究，这些患者被诊断为II-IV期中级或高级非霍奇金淋巴瘤，且此前未接受过治疗。患者被随机分配接受CHOP或CHOP/VIA方案治疗。
排除14例不可评估病例后，62例患者（52.5%）接受CHOP方案治疗，56例（47.5%）接受CHOP/VIA方案治疗。两组之间的主要预后因素无显著差异。114例患者（CHOP组61例，CHOP/VIA组53例）的治疗反应可评估，接受CHOP方案治疗的39例患者（64%）达到完全缓解（CR）,2例（3%）达到部分缓解（PR），而在CHOP/VIA组中，CR和PR率分别为63%（34/53）和7%（4/53）。接受CHOP方案治疗的14例患者（36%）和接受CHOP/VIA方案治疗的12例患者（35%）最终复发，36个月时的复发精算风险分别为43%和40%。中位生存期为37个月。两个治疗组之间未发现差异，CHOP组从诊断开始36个月时的总生存率为53.5%（95%CI：40-67），CHOP/VIA组为48%（95%CI：34-62）。最后，两组的毒性无差异。
在本研究中，对于侵袭性非霍奇金淋巴瘤患者，化疗方案CHOP和CHOP/VIA在治疗反应、反应持续时间、生存率和毒性方面显示出相似的结果。
